Neoadjuvant disitamab vedotin plus perioperative toripalimab showed promising efficacy and acceptable safety in patients with HER2-expressing MIBC, according to Xinan Sheng, MD.

Dr. Park shares the three biggest takeaways, in his opinion, to have come out of the ASCO GU Symposium, highlighting studies ...

Discover a study that found that the combination of durvalumab and tremelimumab with concurrent radiotherapy is a feasible ...

A man in his 50s presented to the emergency department with a complaint of progressively increasing swelling in the lower abdomen. Investigations revealed a large pelvic mass for which a fine needle ...

Endometriosis, a condition where tissue similar to uterine tissue grows outside the uterus, affects many women in the ...

Dr. Rohan Patel, senior uro-oncologist and robotic surgeon in Ahmedabad, successfully performs rare robotic surgery on a ...

Gene's lead asset shows high complete response rates in BCG-unresponsive NMIBC patients. Click here to read why ENGN stock is ...

Dr. Chandler Park helps patients with genitourinary cancers, including both prostate and bladder, understand the importance ...